Opinion

Video

Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC

Author(s):

Joyce A. O'Shaughnessy, MD,Melinda L. Telli, MD

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.

Video content above is prompted by the following question:

  • What are the standard-of-care regimens for first-line treatment of HER2+ metastatic breast cancer (mBC)?
Related Videos
Sagar D. Sardesai, MBBS
DB-12
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Ritu Salani, MD
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Related Content
Lasofoxifene in Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 19th 2024

Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer

Francine Foss, MD, professor, medicine (hematology) and dermatology, director, Multidisciplinary T Cell Lymphoma Program, Yale School of Medicine; scientific leader, Lymphoma CRT, Yale Cancer Center
October 17th 2024

FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 16th 2024

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Rory Shallis, MD, assistant professor, medicine and hematology, Yale School of Medicine, Yale New Haven Health
September 26th 2024

How Luspatercept Could Shake Up MDS Management—With Rory Shallis, MD

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
December 15th 2024

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/8